

# SLx-2119

Catalog No: tcsc0776



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

911417-87-3

**Formula:**

$C_{26}H_{24}N_6O_2$

**Pathway:**

TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage

**Target:**

ROCK;ROCK;ROCK

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 29$  mg/mL (64.09 mM)

**Alternative Names:**

ROCK inhibitor;KD-025

**Observed Molecular Weight:**

452.51


## Product Description

SLx-2119 is a selective inhibitor of **ROCK2** with **IC<sub>50</sub>** of 105 nM, more than 200 fold selectivity over ROCK1 (IC<sub>50</sub>=24 μM).

IC50 & Target: IC50: 105 nM (ROCK2)<sup>[1]</sup>

**In Vitro:** SLx-2119 (40 μM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASM. The microarray hybridized with aRNA from HMVEC treated with SLx-2119, shows a 5-times higher background than the other arrays<sup>[1]</sup>.

**In Vivo:** KD025 (100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. KD025 is at least as efficacious in aged, diabetic or female mice, as in normal adult males<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!